Pinealon: The Brain Recovery Peptide Under the Microscope
Last updated: March 2026
Pinealon (EDR) is a synthetic tripeptide of 3 amino acids — glutamic acid, aspartic acid, and arginine — developed by Vladimir Khavinson's lab at the St. Petersburg Institute of Bioregulation. Unlike surface receptor binders, it enters the cell nucleus and directly interacts with DNA. Clinical studies cover TBI recovery, memory improvement, and neuroprotection under hypoxic conditions.
Clinically Studied
Rate in TBI Trial
(Glu-Asp-Arg)
📋 On this page
Four Mechanisms of Action
Pinealon (EDR) is a tripeptide consisting of glutamic acid, aspartic acid, and arginine. Like all Khavinson bioregulators, it doesn't bind surface receptors — it enters the cell nucleus and interacts directly with DNA.
Protects neurons under hypoxic (low oxygen) stress via activation of innate antioxidant systems. Reduces oxidative damage in brain tissue — relevant to TBI, stroke, and neurodegenerative conditions where hypoxia drives cell death.
Pinealon enters the cell nucleus, interacts with DNA promoter regions and histones — the same mechanism class as Epitalon. In Alzheimer's mouse model (PMC7795577), EDR regulated gene expression involved in AD pathogenesis.
Influences serotonin synthesis pathways in the brain. This modulation may explain the emotional balance improvements seen in the TBI clinical trial, as well as sleep architecture effects — Pinealon has been observed to improve REM and deep sleep duration.
Suppresses NMDA receptor-linked excitotoxicity — the process by which excessive glutamate signaling destroys neurons. This is directly relevant to TBI, ischemic stroke, and neurotoxicity conditions where glutamate flooding causes secondary brain damage.
Key Findings from Published Research
Spanning the TBI clinical trial, Alzheimer's animal model, and preclinical mechanistic data.
Pinealon has actual human data — a clinical trial in 72 TBI patients using oral Pinealon + standard care vs standard care alone. This is more human evidence than most research peptides. That said, it's a single study from a Russian clinical program. Western RCT replication is still needed.
The TBI Clinical Trial
The most significant human data on Pinealon — 72 patients with traumatic brain injury treated with oral Pinealon plus standard therapy vs. standard therapy alone.
the trial
working memory
improved
Pinealon + Epitalon Stack
The most common Khavinson bioregulator combination — two pineal-origin peptides with complementary mechanisms.
The rationale: Epitalon targets pineal function and cellular longevity. Pinealon targets brain cortex cells and cognitive recovery. Used together in Khavinson's protocol — particularly for patients with cognitive decline or sleep-disrupted neurology. No human RCT data exists for this specific combination. The synergy is mechanistically plausible but not yet formally proven.
Dosing Protocols
Doses used in research and Khavinson's clinical program. Not medical prescriptions — research context only.
- Dose: 1–2 mg per day
- Used in the 72-patient TBI trial (oral route)
- Tripeptides survive digestion via PEPT1/PEPT2 transporters
- Lower bioavailability than injectable form
- Typically taken on empty stomach for maximum absorption
- Dose: 200–500 mcg per day
- Higher bioavailability than oral
- Rotate injection sites (abdomen or thigh)
- Cycle: 10–30 days on, 2–3 months off
- FDA Status: NOT approved. Research compound only.
Know the Limitations
Study Citations
Primary research behind the data on this page.
Key Takeaways
Honest assessment of where Pinealon research stands as of 2026.
- 59.4% of TBI patients showed improved working memory (n=72 human trial)
- Headaches, emotional balance, and cognitive performance improved in TBI cohort
- EDR regulated AD-related gene expression in Alzheimer's mouse model
- Neuroprotective under hypoxic conditions via antioxidant system activation
- Suppresses NMDA-linked excitotoxicity — mechanistically relevant to TBI and stroke
- Modulates serotonin synthesis — explains emotional/sleep effects
- Orally bioavailable — tripeptide survives GI transit
- Whether TBI results replicate in Western RCTs with blinded controls
- Efficacy in healthy individuals (not just TBI patients)
- Alzheimer's mouse model results notoriously poor predictors of human outcomes
- Long-term safety profile in humans
- Optimal dosing and cycle length for different indications
- Drug interaction profile
- Whether injectable vs oral produces meaningfully different outcomes
🔬 Verified Research Source
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports HighPeptides at no extra cost. All Swiss Chems products include third-party lab testing certificates.
🛒 Recommended Products
Sleep optimization and cognitive support products relevant to Pinealon's research applications.
Affiliate links help support HighPeptides at no extra cost to you.
Related Resources
Pinealon & Hypothalamic Sleep Regulation
Pinealon's primary tissue target is the pineal gland, but its upstream action on hypothalamic function is critical to understanding its sleep effects. The hypothalamus — specifically the suprachiasmatic nucleus (SCN) and the ventrolateral preoptic area (VLPO) — contains the master circadian oscillator and the primary sleep-promoting neurons in the brain.
Age-related hypothalamic degeneration contributes to fragmented sleep, delayed melatonin onset, and blunted circadian amplitude — the same changes Pinealon's neuroprotective mechanism aims to reverse. By supporting hypothalamic peptide synthesis and reducing oxidative stress in this region, Pinealon may help restore the feedback loop between the SCN and the pineal gland that drives normal melatonin rhythms.
In a complete sleep protocol, Pinealon complements Epithalon: Epithalon works at the pineal (melatonin production), while Pinealon works upstream in the hypothalamus (circadian timing signal). The combination is commonly included in the 10-day Peralta circadian reset protocol.
→ Sleep Optimization: The Complete Protocol🔗 Related Resources
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and informational purposes only. It is not medical advice, and nothing here should be interpreted as a recommendation to use Pinealon or any peptide. Pinealon (EDR) is NOT approved by the FDA or EMA for human use. It is a research compound. Human data comes primarily from a Russian clinical program and has not been replicated in Western randomized controlled trials. The Alzheimer's mouse model data has not been validated in human trials. Always consult a qualified healthcare provider before making any health decisions. HighPeptides does not sell peptides or endorse their use outside of legitimate research settings.